1. Market Research
  2. > Healthcare Market Trends
  3. > Healthcare Analysis & Statistics in Japan, October 2019

Healthcare Analysis & Statistics in Japan, October 2019

Customer Support

Talk to Veronica

+1 718 514 2762

Publishers

  • All
    • Pharma Intelligence

All regions

data types

1-30 of about 100 reports

Cyramza

Cyramza

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewCyramza (ramucirumab; Eli Lilly) is a fully human vascular endothelial growth factor receptor (VEGFR)-2-directed immunoglobulin G1 monoclonal antibody that binds to the extracellular domain ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Nexavar

Nexavar

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewNexavar (sorafenib; Bayer/Amgen) is an orally available, multi-targeted tyrosine kinase inhibitor that is directed against several targets, including CRAF, BRAF, RET, KIT, FMS-like tyrosine ...

  • Industries : Pathology, Cancer, Therapy
  • Countries : United States, Japan, European Union
Opdivo

Opdivo

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewOpdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) is a fully human immunoglobulin G4 PD-1 immune checkpoint inhibitor that binds to the checkpoint receptor PD-1 expressed on activated ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan
Lenvima

Lenvima

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewLenvima (lenvatinib; Eisai/Merck and Co) is an orally available small molecule inhibitor of multiple tyrosine kinases, including vascular endothelial growth factor receptor (VEGFR), platelet-derived ...

  • Industries : Pathology, Cancer
  • Countries : United States, Japan, European Union
Keytruda

Keytruda

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewKeytruda (pembrolizumab; Merck and Co) is a humanized monoclonal antibody designed to inhibit the PD-1 co-inhibitory receptor. The interaction between PD-1 and its primary ligand, PD-L1, inhibits ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Stivarga

Stivarga

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewStivarga (regorafenib; Bayer/Amgen) is an orally available small molecule inhibitor that is currently approved for the treatment of previously treated hepatocellular carcinoma patients. It ...

  • Industries : Pathology, Cancer
  • Countries : United States, Japan, European Union
Cabometyx

Cabometyx

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewCabometyx (cabozantinib; Exelixis/Ipsen/Takeda) is an orally available small molecule inhibitor which has been shown to suppress tumor growth and metastasis by inhibiting the activity of multiple ...

  • Industries : Pathology, Cancer
  • Countries : United States, Japan, European Union
Imfinzi

Imfinzi

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewImfinzi (durvalumab; AstraZeneca) is a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The interaction between PD-L1 and its receptor, programmed death-1 (PD-1), ...

  • Industries : Pathology, Cancer
  • Countries : European Union, Japan, United States
Global Market for Fracture Fixation Devices

Global Market for Fracture Fixation Devices

  • $ 4750
  • Industry report
  • August 2019

OverviewThis medical market and technology report provides a comprehensive discussion of the global market for fracture fixation devices. Geographic markets covered by this analysis include the US, Japan, ...

  • Industries : Health Services
  • Countries : United States, World, Japan
Prostate Cancer Diagnostics and Minimally Invasive Treatments Market

Prostate Cancer Diagnostics and Minimally Invasive Treatments Market

  • $ 4750
  • Industry report
  • July 2019

This report includes a discussion of leading products, new technologies, market forecasts, drivers and limiters, competitors, trends and opportunities in the nearly $1bn Prostate Cancer Diagnostics and ...

  • Industries : Cancer, Pathology, Diagnostics
  • Countries : United States, Japan
Stribild

Stribild

  • $ 10000
  • Industry report
  • June 2019

Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Japan Tobacco) is a single-tablet regimen for the treatment of HIV-1 infection. It is a co-formulation of marketed ...

  • Industries : Therapy
  • Countries : United States, European Union, Japan
Surgical Heart Valve Management Products

Surgical Heart Valve Management Products

  • $ 4750
  • Industry report
  • May 2019

This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the surgical heart valve repair (annuloplasty) systems, surgical heart valve replacement products, ...

  • Industries : Medical Device, Cardiovascular Devices
  • Countries : World, United States, Japan
General and Pelvic Endoscopic Surgery

General and Pelvic Endoscopic Surgery

  • $ 4750
  • Industry report
  • May 2019

This Meddevicetracker report provides an analysis of the market for general and pelvic endoscopic surgery products in the US, five major EU markets, Japan, and the rest of the world. Market segments covered ...

  • Industries : Endoscopic Device
  • Countries : World, United States, Japan
Cymbalta

Cymbalta

  • $ 10000
  • Industry report
  • March 2019

Eli Lilly’s Cymbalta (duloxetine), a serotonin-norepinephrine reuptake inhibitor, was initially approved in the US in August 2004 for the treatment of major depressive disorder. The company has since ...

  • Industries : Pathology, Chronic Disease, Therapy, Mental Health
  • Countries : United States, Japan, European Union
Abilify/Abilify Maintena, Pharma Intelligence

Abilify/Abilify Maintena, Pharma Intelligence

  • $ 10000
  • Industry report
  • March 2019

Abilify (aripiprazole; Otsuka/Lundbeck) is an atypical antipsychotic that contains aripiprazole, a partial agonist of dopamine receptor D2 and serotonin receptor 5-HT1A, and antagonist of the 5-HT2A ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union
Latuda

Latuda

  • $ 10000
  • Industry report
  • March 2019

Latuda (lurasidone; Sumitomo Dainippon/Angelini) contains the atypical antipsychotic lurasidone, which acts as an antagonist of dopamine receptors D2, and serotonin receptors 5-HT2A. By inhibiting the ...

  • Industries : Mental Health, Pathology
  • Countries : Japan, United States, Germany, Italy, Spain, United Kingdom
Seroquel/Seroquel XR, Pharma Intelligence

Seroquel/Seroquel XR, Pharma Intelligence

  • $ 10000
  • Industry report
  • March 2019

The Seroquel franchise contains quetiapine, which acts as an antagonist at multiple neurotransmitter receptors in the brain, such as serotonin 5-HT1A and 5-HT2, dopamine D1 and D2, histamine H1, and adrenergic ...

  • Industries : Mental Health, Pathology
  • Countries : United States, European Union, Japan
Rexulti

Rexulti

  • $ 10000
  • Industry report
  • March 2019

Rexulti (brexpiprazole) is Otsuka’s latest atypical antipsychotic, approved simultaneously in the US for schizophrenia and major depressive disorder in July 2015. The drug acts similarly to Abilify (aripiprazole; ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union
Afinitor

Afinitor

  • $ 10000
  • Industry report
  • March 2019

Afinitor (everolimus; Novartis) is an orally available analog of the mammalian target of rapamycin (mTOR), which mediates the signal transduction pathways required for cell cycle progression from G1 to ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Sutent

Sutent

  • $ 10000
  • Industry report
  • March 2019

Sutent (sunitinib; Pfizer) is an orally available multi-targeted tyrosine kinase inhibitor which specifically inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived growth facto ...

  • Industries : Cancer, Therapy, Pathology
  • Countries : United States, Japan, European Union
Votrient

Votrient

  • $ 10000
  • Industry report
  • March 2019

Votrient (pazopanib; Novartis) is an oral angiogenesis inhibitor targeting the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-KIT. Preclinical ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Avastin

Avastin

  • $ 10000
  • Industry report
  • March 2019

Avastin (bevacizumab; Genentech/Roche/Chugai) is a humanized immunoglobulin G1 monoclonal antibody directed against vascular endothelial growth factor (VEGF).

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Inlyta

Inlyta

  • $ 10000
  • Industry report
  • March 2019

Inlyta (axitinib; Pfizer) is a kinase inhibitor designed to selectively inhibit vascular endothelial growth factor receptor-1.

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Torisel

Torisel

  • $ 10000
  • Industry report
  • March 2019

Torisel (temsirolimus; Pfizer) is an inhibitor of mammalian target of rapamycin (mTOR), which is an intracellular protein that has been implicated in multiple growth-related cellular functions.

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
CB-839

CB-839

  • $ 10000
  • Industry report
  • March 2019

Drug OverviewCancer cells are known to rely on glycolysis as an energy source. CB-839 (Calithera Biosciences) inhibits the glutaminase enzyme, reducing the ability of cancer cells to utilize glutamine ...

  • Industries : Cancer, Therapy, Pathology, Oncology
  • Countries : United States, Japan, European Union
Renal cell cancer (RCC) disease forecast and market analysis to 2038

Renal cell cancer (RCC) disease forecast and market analysis to 2038

  • $ 22000
  • Industry report
  • March 2019

DISEASE OVERVIEWRenal cell carcinoma (RCC) is a tumor that originates in the renal cortex, the outer part of the kidney between the renal capsule and the renal medulla. Around 85% of all malignant kidney ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan
Alzheimer’s Disease Market and Forecast Analysis 2034

Alzheimer’s Disease Market and Forecast Analysis 2034

  • $ 22000
  • Industry report
  • February 2019

Disease OverviewAlzheimer’s disease is an irreversible, progressive, neurodegenerative, and fatal disease that slowly affects memory, cognition, and function. Alzheimer’s disease is the most common ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union
Hepatocellular Cancer Disease Coverage Forecast and Market Analysis to 2035

Hepatocellular Cancer Disease Coverage Forecast and Market Analysis to 2035

  • $ 22000
  • Industry report
  • February 2019

DISEASE OVERVIEWMalignant tumors of the liver are primarily adenocarcinomas, with two major cell types: hepatocellular carcinoma (HCC), and cholangiocarcinoma. Liver cancer is the third-leading cause of ...

  • Industries : Pathology, Energy, Coal, Energy & Environment
  • Countries : United States, European Union, Japan
Finerenone

Finerenone

  • $ 10000
  • Industry report
  • February 2019

Drug OverviewFinerenone (Bayer) is a third-generation potent and selective oral, non-steroidal mineralocorticoid receptor antagonist (MRA). It blocks the detrimental effects due to over-activation of the ...

  • Industries : Therapy, Chronic Disease, Pathology
  • Countries : United States, Japan, European Union, Europe
Farxiga

Farxiga

  • $ 10000
  • Industry report
  • February 2019

Drug OverviewFarxiga (dapagliflozin; AstraZeneca/Ono Pharmaceutical) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class. It is approved for the treatment of type 2 diabetes ...

  • Industries : Chronic Disease, Pathology, Therapy
  • Countries : United States, Japan, European Union

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on